Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to provi...
Accelerate Diagnostics, Inc. is an in vitro dia...
Jasperate, Inc. is a startup company in the truest sense. We have a strong managem...
Jasperate, Inc. is a startup company in the tru...
Axcella is designing and developing AXA Candidates, compositions of endogenous met...
Axcella is designing and developing AXA Candida...
We exist to create an alternate future for people living with neurodegenerative di...
We exist to create an alternate future for peop...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
Aridis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the develop...
Aridis Pharmaceuticals, Inc. is a biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.